Table 1. List of significant differentially expressed proteins identified in plasma from patients with SARS.
| Spot | Protein name | Swiss-Prot entry | Sequence coverage, % | pl/mass, kDa | Regulation | Average volume*, P/N | Functions† |
|---|---|---|---|---|---|---|---|
| Acute Phase Proteins | |||||||
| 1 | SAA protein | P02735 | 35 | 5.9/12 | ↑ (22/22)‡ | 1.78/ND | a, b, c, d |
| 2 | SAA protein | P02735 | 66 | 5.9/12 | ↑ (22/22) | 1.61/ND | a, b, c, d |
| 3 | Transthyretin | P02766 | 60 | 5.4/14 | ↓ (22/22) | 0.56/5.69 | a, b |
| 4 | Transthyretin | P02766 | 70 | 5.4/14 | ↓ (22/22) | 0.29/0.82 | a, b |
| 5 | Transthyretin (polymer) | P02766 | 40 | 5.4/14 | ↑ (17/22) | 0.34/ND | a, b |
| 6 | Transthyretin (polymer) | P02766 | 68 | 5.4/14 | ↑ (20/22) | 0.28/0.12 | a, b |
| 7 | Mannose-binding protein | P11226 | 16§ | 5.4/24 | ↑ (18/22) | 0.02/ND | a, c |
| 8 | Inter-α-trypsin inhibitor heavy chain H4(35kDa fragment) | Q14624 | 41 | 6.3/27 | ↑ (8/22) | 0.03/ND | a, e, g, l |
| 9 | Inter-α-trypsin inhibitor heavy chain H4(35kDa fragment) | Q14624 | 3§ | 6.3/27 | ↑ (22/22) | 0.08/ND | a, e, g, l |
| 10 | Inter-α-trypsin inhibitor heavy chain H4(35kDa fragment) | Q14624 | 2-3§ | 6.3/27 | ↑ (22/22) | 0.25/0.02 | a, e, g, l |
| 11 | α-1-antitrypsin (fragment) | P01009 | 31-40 | 5.4/44 | ↑ (19/22) | 0.27/ND | a, e, f, o |
| 12 | α-1-antitrypsin (fragment) | P01009 | 9-24§ | 5.4/44 | ↑ (22/22) | 0.82/ND | a, e, f, o |
| 13 | α-1-antitrypsin | P01009 | 35-5§ | 5.4/44 | ↑ (21/22) | 7.96/1.01 | a, e, f, o |
| 14 | Haptoglobin (β chain) (fragment) | P00738 | 19-22§ | 6.3/27 | ↑ (14/22) | 0.39/ND | a, b, c, d |
| 15 | Haptoglobin (β chain) | P00738 | 8-16§ | 6.3/27 | ↑ (22/22) | 4.20/0.26 | a, b, c, d |
| 16 | Complement C3 (fragment) | P01024 | 7§ | 6.0/185 | ↑ (4/22) | 0.50/ND | a, c |
| 17 | α-2-HS glycoprotein | P02765 | 11§ | 4.5/30 | ↑ (22/22) | 0.73/0.52 | a, c |
| 18 | Angiotensinogen | P01019 | 22§ | 5.6/50 | ↑ (17/22) | 0.15/ND | a, e, k, m |
| 19 | Inter-α-trypsin inhibitor heavy chain H4(70kDa fragment) | Q14624 | 7§ | 5.9/71 | ↑ (11/22) | 0.08/ND | a, e, g, l |
| 20 | Complement C4 (fragment) | P01028 | 1§ | 5.7/192 | ↑ (13/22) | 0.06/ND | a, c |
| Antioxidation | |||||||
| 21 | Peroxiredoxin 2 | P32119 | 30§ | 5.7/22 | ↑ (22/22) | 0.32/ND | c, d, l, o |
| 22 | Peroxiredoxin 1 or 2 | P32119 | 6§ | 5.7/22 | ↑ (9/22) | 0.10/ND | c, d, l, o |
| 23 | Peroxiredoxin 1 or 2 | P32119 | 6§ | 5.7/22 | ↑ (5/22) | 0.03/ND | c, d, l, o |
| 24 | Glutathione peroxidase | P22352 | 28§ | 7.8/23 | ↑ (22/22) | 0.22/ND | d |
| Transport Proteins | |||||||
| 25 | Plasma retinol-binding protein | P02766 | 21§ | 5.3/21 | ↑ (22/22) | 0.22/ND | b |
| 26 | Apolipoprotein A-VI (fragment) | P06727 | 11§ | 5.2/43 | ↓ (12/22) | 0.02/0.21 | b |
| 27 | Apolipoprotein E | P02649 | 20§ | 5.5/34 | ↑ (15/22) | 0.01/ND | b, n |
| 28 | Complement factor H-related protein 1 | P02647 | 3§ | 7.5/36 | ↑ (22/22) | 0.29/0.17 | b, c |
| 29 | Vitamin D-binding protein | P02774 | 21§ | 5.2/51 | ↑ (22/22) | 0.14/ND | b |
| 30 | Vitamin D-binding protein | P02774 | 12§ | 5.2/51 | ↑ (22/22) | 0.19/ND | b |
| 31 | Apolipoprotein A-1 (polymer) | P02753 | 44 | 5.3/28 | ↑ (19/22) | 0.04/ND | b, c, g |
| Protease and Protease inhibitors | |||||||
| 32 | Kininogen | P01042 | 5§ | 6.2/70 | ↑ (16/22) | 0.07/ND | c, e, f |
| 33 | Pigment epithelium-derived factor | P36955 | 12§ | 6.0/45 | ↑ (22/22) | 0.02/0.01 | h, i, k |
| 34 | Thrombin | P00734 | 15§ | 8.3/34 | ↑ (2/22) | 0.46/ND | f, i |
| 34 | Antithrombin III | P01008 | 51 | 6.0/49 | ↑ (2/22) | 0.46/ND | e, f, k, o |
| 35 | Antithrombin III (fragment) | P01008 | 5§ | 6.0/ND | ↑ (19/22) | 0.06/ND | e, f, o |
| Others | |||||||
| 36 | Leucine-rich α-2-glycoprotein | P02750 | 49 | 5.7/34 | ↑ (22/22) | 0.58/0.07 | j |
| 37 | Fibrinogen-like protein 1 | Q08830 | 6§ | 5.5/34 | ↑ (10/22) | 0.07/0.03 | h |
| 38 | Tetranectin | P05452 | 5§ | 5.8/20 | ↑ (18/22) | 0.04/ND | g |
*
The average spot volume (%) in normal controls (N) and in SARS patients (P). ND, not detectable.
†
a, acute phase protein; b, transport/scavenger proteins; c, immune modulation; d, antioxidant; e, protease inhibitor; f, coagulation; g, tissue remodeling; h, signaling proteins; i, protease; j, hemostasis; k, antiangiogenesis; l, antiapoptosis; m, regulation of blood pressure; n, lipid metabolism; o, antiviral activity (based on the description on http://harvester.embl.de).
‡
Occurrence in 22 gels.
§
Spots were further confirmed by LC-MS/MS.